Why Mitochondria Matter

Mitochondria play a central role in:

  • cellular energy production (ATP)
  • muscle performance and endurance
  • cellular stress responses

When mitochondria are dysfunctional, fatigue, exercise intolerance, and reduced muscle performance can become major issues—especially in rare mitochondrial diseases.

What Does the Human Research Say?

SS-31/elamipretide has been evaluated in randomized clinical research in adults with primary mitochondrial myopathy. In a randomized dose-escalation trial, researchers reported improvement in a functional walking test (6-minute walk test) after short-term treatment, with an acceptable safety profile in the study context.

Later research has continued exploring outcomes, dosing strategies, and longer-term effects (including crossover trial designs), reflecting sustained scientific interest.

FDA Approval: Forzinity (Elamipretide) for Barth Syndrome

A key reason SS-31 stands out is that elamipretide (Forzinity) received FDA accelerated approval (Sept 19, 2025) as the first treatment for Barth syndrome, indicated to improve muscle strength in adult and pediatric patients meeting label criteria.

That doesn’t mean SS-31 is “for everything,” but it does mean:

  • it’s not just theoretical—there’s a real regulatory pathway and medical indication
  • there’s a clearer safety and manufacturing framework for the approved product

Safety Notes (High-Level)

In clinical development and FDA documents, the most commonly discussed tolerability issues include injection-site reactions and standard monitoring considerations described in the prescribing information.

(Always defer to prescribing information and treating clinicians for medical decisions.)

Who Might Be Interested (Educational, Not Medical Advice)

People researching mitochondrial peptides are often trying to understand:

  • evidence quality (human vs animal vs theory)
  • realistic outcomes vs hype
  • medical vs non-medical product claims

If you’re exploring SS-31 information online, focus on human trials and regulatory documentation, not marketing screenshots.

Quick FAQ

Is SS-31 FDA approved?
Elamipretide is FDA-approved as Forzinity for Barth syndrome under accelerated approval.

Is all “SS-31” online the same thing?
Not necessarily. FDA-approved products follow controlled manufacturing standards; other sources may not.

References (for your blog)

  • FDA press announcement: accelerated approval of Forzinity (elamipretide).
  • FDA approval letter (NDA 215244) and prescribing information highlights.
  • Randomized dose-escalation trial in primary mitochondrial myopathy (Karaa et al., 2018).
  • FDA integrated review summary (NDA 215244).

Internal link ideas: “What are peptides?”, “How to read clinical studies”, “Mitochondrial health basics”.

Related Posts